IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results From a Multicenter Phase 1 Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 12
页数：3
相关论文
共 50 条
  • [21] Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial
    Bagot, Martine
    Kim, Youn
    Zinzani, Pier Luigi
    Dalle, Stephane
    Beylot-Barry, Marie
    Ortiz-Romero, Pablo L.
    Cambalia, Andrea
    Dereure, Olivier
    Mortier, Laurent
    Jacobsen, Eric
    Battistella, Maxime
    Gru, Alejandro
    Moins-Teisserenc, Helene
    Paiva, Christine
    Boyer-Chammard, Agnes
    Rotolo, Federico
    Azim, Hatem A.
    Porcu, Pierluigi
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : S20 - S21
  • [22] Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
    Haddad, E
    Paczesny, S
    Leblond, V
    Seigneurin, JM
    Stern, M
    Achkar, A
    Bauwens, M
    Delwail, V
    Debray, D
    Duvoux, C
    Hubert, P
    de Ligny, BH
    Wijdenes, J
    Durandy, A
    Fischer, A
    BLOOD, 2001, 97 (06) : 1590 - 1597
  • [23] International, Multicenter Phase II Trial With Humanized Anti-GD2 Monoclonal Antibody Naxitamab for Treatment of Refractory/Relapsed High-Risk Neuroblastoma: Efficacy and Safety Data
    Mora, J.
    Chan, G.
    Morgenstern, D.
    Nysom, K.
    Bear, M.
    Dalby, L. W.
    Lisby, S.
    Kushner, B.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S294 - S294
  • [24] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
    Apolo, Andrea B.
    Infante, Jeffrey R.
    Balmanoukian, Ani
    Patel, Manish R.
    Wang, Ding
    Kelly, Karen
    Mega, Anthony E.
    Britten, Carolyn D.
    Ravaud, Alain
    Mita, Alain C.
    Safran, Howard
    Stinchcombe, Thomas E.
    Srdanov, Marko
    Gelb, Arnold B.
    Schlichting, Michael
    Chin, Kevin
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2117 - +
  • [25] BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
    Chu, Quincy
    Leighl, Natasha B.
    Surmont, Veerle
    van Herpen, Carla
    Sibille, Anne
    Markman, Ben
    Clarke, Stephen
    Juergens, Rosalyn A.
    Rivera, Mirelis Acosta
    Andelkovic, Vladimir
    Rudin, Charles M.
    Snow, Stephanie
    Kim, Dong-Wan
    Sanatani, Michael
    Lin, Hongxia
    Sanghavi, Kinjal
    Tannenbaum-Dvir, Sarah
    Basciano, Paul
    Lathers, Deanne
    Urbanska, Katarzyna
    Kollia, Georgia
    He, Chunsheng
    Dipiero, Andrew
    Liu, Yu
    Ready, Neal
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
  • [26] Anti-KIR(1-7F9): A fully human monoclonal antibody (mAb) that blocks KIR2DL1,-2 and-3, promoting natural killer (NK) cell-mediated lysis of tumor cells in vitro and in vivo
    Wagtmann, Nicolai
    Andre, Pascale
    Zahn, Stefan
    Spee, Pieter
    Anfossi, Nicolas
    Gauthier, Laurent
    Blaser, Bradley W.
    Caligiuri, Michael A.
    Capanni, Marusca
    Ruggeri, Loredana
    Velardi, Andrea
    Romagne, Francois
    BLOOD, 2007, 110 (11) : 179A - 179A
  • [27] Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies
    Gong, Jifang
    Liu, Chang
    Yao, Jun
    Xue, Junli
    Dai, Jing
    Ji, Yinghua
    Markman, Ben
    Hiong, Alison
    Yang, Xiuli
    Zhao, Rusen
    Zheng, Yi
    Li, Qingshan
    Wu, Jun
    Barve, Minal A.
    Ariyapperuma, Mihitha Hashara
    Richardson, Gary Edward
    Qin, Xia
    Qin, Crystal Ying
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
    Rasche, Leo
    Duell, Johannes
    Castro, Ines C.
    Dubljevic, Valentina
    Chatterjee, Manik
    Knop, Stefan
    Hensel, Frank
    Rosenwald, Andreas
    Einsele, Hermann
    Topp, Max S.
    Braendlein, Stephanie
    HAEMATOLOGICA, 2015, 100 (03) : 377 - 384
  • [29] Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
    Thieblemont, Catherine
    Munoz, Javier
    Tucci, Alessandra
    Visco, Carlo
    Cartron, Guillaume
    Corradini, Paolo
    Flinn, Ian W.
    Gastinne, Thomas
    Bouabdallah, Kamal Krimo
    Arcaini, Luca
    Nowakowski, Grzegorz S.
    Roulin, Louise
    Topp, Max
    Jauhari, Shekeab
    Vucinic, Vladan
    Martin, Peter
    Gkasiamis, Argyrios
    Drew, James
    Rao, Parth
    Kaplan, Mark
    Cheng, Yiming
    Li, Ju
    Morschhauser, Franck
    BLOOD, 2022, 140
  • [30] Results of a phase 2 trial of HGS-ETR1 (Agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Younes, A
    Vose, JM
    Zelenetz, AD
    Smith, MR
    Burris, H
    Ansell, S
    Klein, J
    Kumm, E
    Czuczman, M
    BLOOD, 2005, 106 (11) : 146A - 147A
12345